Antibody Information
General Information of This Antibody
Antibody ID | ANI0OAONZ |
|||||
---|---|---|---|---|---|---|
Antibody Name | Anti-CD46 fully human antibody |
|||||
Synonyms |
Anti-CD46 fully human antibody (ab)
Click to Show/Hide
|
|||||
Antibody Type | Monoclonal antibody (mAb) |
|||||
Antibody Subtype | Humanized IgG1 |
|||||
Antigen Name | Membrane cofactor protein (CD46) |
Antigen Info |
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
FOR-46 [Phase 1/2]
Identified from the Human Clinical Data
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Partial Response (PR) |
22.20%
|
|||
Patients Enrolled |
Metastatic castration-resistant prostate cancer (CRPC).
|
||||
Administration Dosage |
Intravenous FOR46 on day 1 of every 21-day cycle. Dose levels ranged from 0.10 mg/kg. the starting dose level, to 3.00 mg/kg. The trial established 2.70 mg/kg to be the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of the agent.
|
||||
Related Clinical Trial | |||||
NCT Number | NCT03575819 | Clinical Status | Phase 1 | ||
Clinical Description |
A phase 1 study of FOR46 administered every 21 days in patients with metastatic castration-resistant prostate cancer (mCRPC).
|
||||
Primary Endpoint |
MtD and phase 1b dose=2.70 mg/kg.
|
||||
Other Endpoint |
18 pts had measurable lesions; 8 of 18 (44.44%) had tumor regression, with 4 (22.22%) confirmed partial responses (PR). The median duration of response is > 14 wks (range 9 -31+ weeks).
|
||||
Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
Related Clinical Trial | |||||
NCT Number | NCT05011188 | Clinical Status | Phase 1/2 | ||
Clinical Description |
A phase 1b/2 study of FOR46 in combination with enzalutamide in patients with metastatic castration resistant prostate cancer.
|
||||
Experiment 3 Reporting the Activity Date of This ADC | [3] | ||||
Related Clinical Trial | |||||
NCT Number | NCT03650491 | Clinical Status | Phase 1 | ||
Clinical Description |
A phase 1 study of FOR46 administered every 21 days in patients with relapsed or refractory multiple myeloma (RRMM).
|
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.